Streetbeat News

PSCH

Invesco S&P SmallCap Health Care ETF

https://www.invesco.com/us/financial-products/etfs/product-detail?ticker=PSCH

Industry

Asset Management

The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices, LLC compiles, maintains and calculates the index, which is designed to measure the performance of securities of small-capitalization U.S. companies in the health care sector, as defined by the Global Industry Classification Standard.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Coya Therapeutics Inc (NASDAQ:COYA), a clinical-stage biotech company, has seen its shares rise by 70% since its IPO in December 2022. The company focuses on developing treatments for neurodegenerative and inflammatory diseases using regulatory T cells (Tregs). CEO Howard Berman highlighted the company's shift towards combination therapies and biologics, similar to approaches in cancer and viral disease treatments. Coya's lead program, COYA 302, is being developed for conditions like ALS, FTD, Parkinson's, and Alzheimer's. The company plans to file an FDA IND in 2Q24 and start a Phase 2 trial for ALS. Despite a recent 2.9% drop in share price, the company received a $5 million investment from the Alzheimer's Drug Discovery Foundation.

Portfolio Pulse from Vandana Singh

May 27, 2024 | 1:43 pm

Fortrea Holdings Inc. (NASDAQ:FTRE) shares plummeted after reporting disappointing Q1 FY24 results and lowering its revenue forecast. The company missed revenue expectations with $662.1 million against a consensus of $754.6 million and reduced its FY24 revenue guidance from $3.14-$3.205 billion to $2.785-$2.855 billion. Adjusted EBITDA and EPS also fell short of expectations, with significant declines from the previous year. Fortrea is in the process of divesting its Endpoint Clinical and Fortrea Patient Access businesses to an affiliate of Arsenal Capital Partners, expected to close in Q2. Investors can also gain exposure to Fortrea through Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH) and Vanguard S&P Small-Cap 600 Value ETF (NYSE:VIOV).

Portfolio Pulse from Lekha Gupta

May 13, 2024 | 3:21 pm

Organon & Co (NYSE:OGN) reported a first-quarter revenue of $1.622 billion, a 5% increase year-over-year, surpassing the consensus of $1.563 billion. The growth was led by an 11% increase in Women's Health revenue, notably from Nexplanon, and a 46% surge in Biosimilar revenue, driven by Ontruzant and Renflexis. Despite a flat performance in Established Brands, the company beat adjusted EPS estimates with $1.22 against a consensus of $0.93. However, adjusted gross margin and EBITDA margin saw slight declines. Organon declared a quarterly dividend of $0.28 per share and reaffirmed its FY24 revenue guidance of $6.2 billion to $6.5 billion. OGN shares rose 2.18% to $19.24. Exposure to Organon's stock can also be gained through SPDR S&P Pharmaceuticals ETF (NYSE:XPH) and Invesco S&P SmallCap Health Care ETF (NASDAQ:PSCH).

Portfolio Pulse from Lekha Gupta

May 02, 2024 | 5:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.